A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum
Objective: To evaluate oral pyridoxine in conjunction with standard therapy in women hospitalized for hyperemesis gravidarum (HG). Methods: Patients with HG were randomized at hospitalization to 20 mg oral pyridoxine thrice daily or to placebo. Intravenous rehydration, metoclopramide and oral thiami...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
2009
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/10851/1/Tan-2009-A_Placebo-Controlled.pdf http://eprints.um.edu.my/10851/ http://www.karger.com/Article/Pdf/181182 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universiti Malaya |
Language: | English |
id |
my.um.eprints.10851 |
---|---|
record_format |
eprints |
spelling |
my.um.eprints.108512014-07-16T00:19:37Z http://eprints.um.edu.my/10851/ A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum Tan, P.C. Yow, C.M. Omar, S.Z. R Medicine Obstetrics Objective: To evaluate oral pyridoxine in conjunction with standard therapy in women hospitalized for hyperemesis gravidarum (HG). Methods: Patients with HG were randomized at hospitalization to 20 mg oral pyridoxine thrice daily or to placebo. Intravenous rehydration, metoclopramide and oral thiamine were also administered. Metoclopramide and thiamine were continued for 2 weeks after discharge. Rehospitalization for HG in the 2-week study period was ascertained, vomiting was recorded by diary, and nausea was evaluated with a 10-point visual analogue scale (VAS) at enrolment, after hospital discharge and on week 1 and 2 reviews. Results: Ninety-two women were included in the analysis. The rehospitalization rate was 37.5 versus 21.1 (relative risk 1.8, 95 confidence interval 0.9-3.7, p = 0.14) for pyridoxine and placebo, respectively. Daily vomiting episodes after discharge were not different (mean +/- SD): 1.9 +/- 2.4 versus 1.4 +/- 1.1, p = 0.28 during week 1 and 1.4 +/- 1.3 versus 1.4 +/- 1.6, p = 0.98 during week 2. Repeated-measures analysis of variance showed no difference in the nausea visual analogue scale (p = 0.59). Conclusion: The use of oral pyridoxine in conjunction with metoclopramide during the inpatient stay and during the 2 weeks after hospital discharge for hyperemesis gravidarum did not improve the rehospitalization rate, the vomiting frequency or the nausea score. Larger studies need to be done. Copyright (C) 2008 S. Karger AG, Basel 2009 Article PeerReviewed application/pdf en http://eprints.um.edu.my/10851/1/Tan-2009-A_Placebo-Controlled.pdf Tan, P.C. and Yow, C.M. and Omar, S.Z. (2009) A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum. Gynecologic and Obstetric Investigation, 67 (3). pp. 151-157. ISSN 0378-7346 http://www.karger.com/Article/Pdf/181182 10.1159/000181182 |
institution |
Universiti Malaya |
building |
UM Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Universiti Malaya |
content_source |
UM Research Repository |
url_provider |
http://eprints.um.edu.my/ |
language |
English |
topic |
R Medicine Obstetrics |
spellingShingle |
R Medicine Obstetrics Tan, P.C. Yow, C.M. Omar, S.Z. A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum |
description |
Objective: To evaluate oral pyridoxine in conjunction with standard therapy in women hospitalized for hyperemesis gravidarum (HG). Methods: Patients with HG were randomized at hospitalization to 20 mg oral pyridoxine thrice daily or to placebo. Intravenous rehydration, metoclopramide and oral thiamine were also administered. Metoclopramide and thiamine were continued for 2 weeks after discharge. Rehospitalization for HG in the 2-week study period was ascertained, vomiting was recorded by diary, and nausea was evaluated with a 10-point visual analogue scale (VAS) at enrolment, after hospital discharge and on week 1 and 2 reviews. Results: Ninety-two women were included in the analysis. The rehospitalization rate was 37.5 versus 21.1 (relative risk 1.8, 95 confidence interval 0.9-3.7, p = 0.14) for pyridoxine and placebo, respectively. Daily vomiting episodes after discharge were not different (mean +/- SD): 1.9 +/- 2.4 versus 1.4 +/- 1.1, p = 0.28 during week 1 and 1.4 +/- 1.3 versus 1.4 +/- 1.6, p = 0.98 during week 2. Repeated-measures analysis of variance showed no difference in the nausea visual analogue scale (p = 0.59). Conclusion: The use of oral pyridoxine in conjunction with metoclopramide during the inpatient stay and during the 2 weeks after hospital discharge for hyperemesis gravidarum did not improve the rehospitalization rate, the vomiting frequency or the nausea score. Larger studies need to be done. Copyright (C) 2008 S. Karger AG, Basel |
format |
Article |
author |
Tan, P.C. Yow, C.M. Omar, S.Z. |
author_facet |
Tan, P.C. Yow, C.M. Omar, S.Z. |
author_sort |
Tan, P.C. |
title |
A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum |
title_short |
A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum |
title_full |
A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum |
title_fullStr |
A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum |
title_full_unstemmed |
A placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum |
title_sort |
placebo-controlled trial of oral pyridoxine in hyperemesis gravidarum |
publishDate |
2009 |
url |
http://eprints.um.edu.my/10851/1/Tan-2009-A_Placebo-Controlled.pdf http://eprints.um.edu.my/10851/ http://www.karger.com/Article/Pdf/181182 |
_version_ |
1643688902684311552 |